Biosimilar considerations for
specialty pharmacies

Key takeaways:

  • Specialty pharmacies are uniquely positioned to educate both patients and
    providers about biosimilars1
  • Staff can answer questions around pricing and communicate the potential savings to payers as well1

Perhaps no group is more important to biosimilar adoption than specialty pharmacies. The opportunity that lies with these stakeholders cannot be overstated.

That’s because specialty pharmacies understand—and need to communicate—the clinical and economic sides of the equation when it comes to the medicines they distribute.1

How much does a particular drug cost? Is it a pharmacy benefit or a medical benefit? When it comes to education and pharmacovigilance around biosimilars, specialty pharmacies play a vital role.1
These stakeholders have been instrumental in the COVID-19 vaccination effort, which increased the opportunity for pharmacists to be involved in the delivery of care.2 More than merely dispersing medicine, specialty pharmacies can handle patient communications because they’ve been at the front lines of these crucial healthcare interactions.1

And they can—and should—play a role in driving savings by helping prescribers understand coverage and pricing around biosimilars. This group is uniquely positioned to help ensure both that patients are getting the best care possible and that the healthcare system as a whole can benefit.

Learn more about the key considerations for biosimilars with each of the following groups.



To learn more about the promise of biosimilars, the impact they can create, and our work in this space, visit the following pages:

1. Byrne M. The Ins and Outs of Specialty Pharmacy. Pharmacy Times. December 6, 2018.
2. Rosenthal M. New Report: Pharmacists Providing Vaccinations More Often Than Physicians. February 13, 2023.